Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
DRUG: HRS-3738
Maximum tolerated dose (MTD), Incidence and category of dose limiting toxicities (DLTs) during the first 28-day cycle of HRS-3738 treatment., From Day 1 to Day 28|RP2D, RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in dose escalation and dose expansion stages., From Day 1 to Day 28
Safety endpoints: adverse events(AEs), serious adverse events（SAEs）, Assess safety and tolerability of HRS-3738 by way of adverse events (CTCAE v5.0)., From Day 1 to 30 days after last dose.|Efficacy endpoints: Overall response rate (ORR), Evaluated using Lugano 2014 criteria and IMWG criteria., From Day 1 to 30 days after last dose.|Efficacy endpoints: Best of response (BOR), Evaluated using Lugano 2014 criteria and IMWG criteria, From Day 1 to 30 days after last dose|Efficacy endpoints: time to response (TTR), Evaluated using Lugano 2014 criteria and IMWG criteria., From Day 1 to 30 days after last dose.|Efficacy endpoints: Duration of response (DoR), Evaluated using Lugano 2014 criteria and IMWG criteria, From Day 1 to 30 days after last dose|Efficacy endpoints: Progression-free survival (PFS), Evaluated using Lugano 2014 criteria and IMWG criteria, From Day 1 to 30 days after last dose|Efficacy endpoints: overall survival (OS)., Evaluated using Lugano 2014 criteria and IMWG criteria., From Day 1 to 30 days after last dose.|Cmax, Maximal plasma concentration, From Day 1 to 30 days after last dose|Tmax, Time to Cmax, From Day 1 to 30 days after last dose|AUC, Area under the plasma concentration-time curve, From Day 1 to 30 days after last dose|t1/2, Terminal-phase elimination half-life, From Day 1 to 30 days after last dose|Vz/F, Apparent volume of distribution during terminal phase after non-intravenous administration, From Day 1 to 30 days after last dose|CL/F, Apparent total clearance of the drug from plasma after oral administration., From Day 1 to 30 days after last dose
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.